TCMD

Tactile Systems Technology, Inc. [TCMD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TCMD Stock Summary

In the News

TCMD Financial details

Company Rating
-
Market Cap
351.17M
Income
28.52M
Revenue
274.42M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
992
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
13.65
Forward P/E
-
PEG
-0.58
P/S
1.26
P/B
1.86
P/C
-
P/FCF
17.25
Quick Ratio
2.71
Current Ratio
3.33
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.21
EPS next Y
-
EPS next Q
-
EPS this Y
-239.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
16.41%
Revenue last 5Y
7.69%
Revenue Q/Q
11.59%
EPS Q/Q
-63.16%
-
-
-
-
SMA20
-
SMA50
-3.45%
SMA100
86.67%
Inst Own
-
Inst Trans
-
ROA
9%
ROE
16%
ROC
0.06%
Gross Margin
68%
Oper. Margin
5%
Profit Margin
9%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.695-26.11
52W High
+4.04%
52W Low
+200.56%
RSI
43
Rel Volume
0.38
Avg Volume
303.08K
Volume
113.81K
Perf Week
-3.77%
Perf Month
-2.1%
Perf Quarter
99.63%
Perf Half Y
100.07%
-
-
-
-
Beta
1.207
-
-
Volatility
0.29%, 1.34%
Prev Close
-1.31%
Price
27.05
Change
-1.02%

Something similar

Top by Market Cap
TSLA
META
VTSAX
BRH.DE
FB2A.DE
Same Sector
ERYP.PA
SHWZ
GDR.L
6823.T
ADCT
Same Price Range
FICS
STAG
FLRT
TGVIX
VERA
Similar Market Cap
GSST
0S9E.L
BUFF
XTC.TO
FTPA

Company Profile

Healthcare Medical - Devices
  • Volume Average 303.08K
  • Market Capitalization 351.17M
  • Employee 992
  • CEO Mr. Daniel L. Reuvers
  • Headquarters Minneapolis,MN,US
  • IPO Date 2016-07-28
  • Website https://www.tactilemedical.com

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.